<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003099</url>
  </required_header>
  <id_info>
    <org_study_id>ID94-029</org_study_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>MDA-ID-94029</secondary_id>
    <secondary_id>NCI-P97-0113</secondary_id>
    <secondary_id>CDR0000065829</secondary_id>
    <nct_id>NCT00003099</nct_id>
  </id_info>
  <brief_title>Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer</brief_title>
  <official_title>Phase II Clinical Trial of N-(4-hydroxyphenyl) Retinamide (4-HPR) and Tamoxifen in Breast Neoplasia, Administration During the Period Between the Diagnostic Core Biopsy and Definitive Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
      development or recurrence of cancer. The use of fenretinide and tamoxifen before surgery may
      be an effective way to prevent the recurrence of or further development of breast cancer.

      PURPOSE: Randomized phase II trial to study the effectiveness of fenretinide and tamoxifen
      given before surgery in treating women with breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the feasibility of identifying surrogate endpoint biomarkers in
      women with breast ductal carcinoma in situ and associated neoplastic and preneoplastic
      lesions. II. Determine whether treatment with fenretinide and tamoxifen administered daily
      will cause significant modulation of proposed surrogate endpoint biomarkers in this patient
      population.

      OUTLINE: This is a randomized, placebo controlled study. Patients are stratified according to
      histological diagnosis (hyperplasia vs carcinoma). All patients undergo a core biopsy and
      fine needle aspiration of the index lesion and are then assigned randomly to a treatment arm.
      Arm I receives tamoxifen and fenretinide daily. Arm II receives a placebo daily. Both arms
      continue for 14-28 days, until definitive surgery or a second biopsy is performed.

      PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study, 50 patients per
      arm.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1996</start_date>
  <completion_date type="Actual">January 2003</completion_date>
  <primary_completion_date type="Actual">June 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fenretinide + Tamoxifen effectiveness given before surgery in treating breast cancer</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1 Tamoxifen + Fenretinide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tamoxifen + Fenretinide daily for 14-28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo daily for 14-28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenretinide</intervention_name>
    <description>Daily for 14-28 days.</description>
    <arm_group_label>Arm 1 Tamoxifen + Fenretinide</arm_group_label>
    <other_name>4-HPR</other_name>
    <other_name>N-(4-hydroxyphenyl) Retinamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen Citrate</intervention_name>
    <description>Daily for 14-28 days.</description>
    <arm_group_label>Arm 1 Tamoxifen + Fenretinide</arm_group_label>
    <other_name>Nolvadex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily for 14-28 days</description>
    <arm_group_label>Arm 2 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Mammogram highly suspicious for ductal carcinoma in situ or early
        invasive carcinoma Branching or linear microcalcifications clustered or distributed
        segmentally in the breast without an associated palpable or mammographic mass Palpable
        thickening or nipple discharge allowed At least 5 mm area of calcification or contain
        enough calcium for core biopsies Small palpable carcinoma (T1 or T2) with no palpable
        axillary lymph nodes (N0) No definitive local therapy Atypical hyperplasia (ductal or
        lobular) and/or carcinoma on initial diagnostic biopsy Hormone receptor status: Not
        specified

        PATIENT CHARACTERISTICS: Age: Over 18 Sex: Female Menopausal status: Not specified
        Performance status: Zubrod 0-2 Life expectancy: Not specified Hematopoietic: Absolute
        granulocyte count greater than 1500/mm3 Platelet count greater than 100,000/mm3 Hepatic:
        Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no greater than 1.5 mg/dL
        Cardiovascular: No uncontrolled congestive heart failure Other: Fasting serum triglycerides
        less than 400 mg/dL Fertile patients must use effective contraception during and for one
        year after completing fenretinide therapy No concurrent serious illness or infection, e.g.,
        septicemia No prior thromboembolic disease No prior degenerative retinal disease

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 5 years
        since prior chemotherapy Endocrine therapy: At least 12 months since prior tamoxifen
        therapy No concurrent estrogen therapy At least 3 months since prior anabolic steroids
        Radiotherapy: No prior radiotherapy to the chest or breast Surgery: See Disease
        Characteristics Other: No vitamin A supplementation greater than 25,000 IU At least 12
        months since prior retinoid therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sonja E. Singletary, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>June 15, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2004</study_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>Tamoxifen</keyword>
  <keyword>Fenretinide</keyword>
  <keyword>Chemoprevention Therapy</keyword>
  <keyword>N-(4-hydroxyphenyl) Retinamide</keyword>
  <keyword>4-HPR</keyword>
  <keyword>Breast Neoplasia</keyword>
  <keyword>Diagnostic Core Biopsy</keyword>
  <keyword>Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Retinamide</mesh_term>
    <mesh_term>Fenretinide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

